Bluebird Nests In Private Equity As Capital Position Goes South
The gene therapy-focused biotech has entered into a deal for private equity firms Carlyle and SK Capital to acquire it amid a shortage of capital and regulatory setback.
The gene therapy-focused biotech has entered into a deal for private equity firms Carlyle and SK Capital to acquire it amid a shortage of capital and regulatory setback.